ANTENGENE-B (06996) announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental new drug application (sNDA) for Xpovio® (selinexor). The approval allows Xpovio® to be used in treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two prior systemic therapies and are ineligible for autologous stem cell transplantation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.